Sep 12, 2022 / 04:30PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Great. All right. Well, thanks, everybody, for joining us. I'm Terence Flynn, the pharma and one of the biotech analysts here at Morgan Stanley, and we're very pleased to have Arcus here with us today. Before we get for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Today from the company, we have Terry Rosen, the company's CEO; and Jennifer Jarrett, the company's COO. But thank you both so much for taking time out of your day to join us today. I really appreciate it.
Maybe, Terry, I thought you could just start and give a high-level overview of kind of the company's pipeline, especially the breadth of the pipeline because it is somewhat different from some of the other development stage biotech companies and then we can go from there.
Terry J. Rosen
Arcus Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot